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Abstract
Background—Cancer patients have an approximately four-fold increased risk of venous 
thromboembolism (VTE) compared with the general population, and cancer patients with VTE 
have reduced survival. Tumor cells constitutively release small membrane vesicles called 
microvesicles (MVs) that may contribute to thrombosis in cancer patients. Clinical studies have 
shown that levels of circulating tumor-derived, tissue factor-positive (TF+) MVs in pancreatic 
cancer patients are associated with VTE.
Objectives—We tested the hypothesis that TF+ tumor-derived MVs (TMVs) activate platelets in 
vitro and in mice.
Materials and Methods—We selected two human pancreatic adenocarcinoma cell lines 
expressing high (BxPc-3) and low (L3.6pl) levels of TF as models to study the effect of TF+ 
TMVs on platelets and thrombosis.
Results and Conclusions—We found that both types of TF+ TMVs activated human platelets 
and induced aggregation in vitro in a TF- and thrombin-dependent manner. Further, injection of 
BxPc-3 TF+ TMVs triggered platelet activation in vivo and enhanced thrombosis in two mouse 
models of venous thrombosis in a TF-dependent manner. Importantly, BxPc-3 TF+ TMV-
enhanced thrombosis was reduced in Par4-deficient mice and in wild-type mice treated with 
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clopidogrel, suggesting that platelet activation was required for enhanced thrombosis. These 
studies suggest that TF+ TMV-induced platelet activation contributes to thrombosis in cancer 
patients.
Introduction
Cancer patients have a four-fold increased risk of venous thromboembolism (VTE) [1–4]. 
VTE in cancer patients is associated with increased mortality [5, 6]. Patients with pancreatic 
cancer have been shown to have a particularly high rate of VTE in comparison to other 
cancer types [5, 7, 8]. Cancer is a heterogeneous group of disorders and therefore it is likely 
that there are multiple mechanisms of cancer-associated VTE. Indeed, many mechanisms 
have been proposed to explain the enhancement of thrombosis with the development of 
cancer, including tissue factor (TF)+ microvesicles (MVs), neutrophils extracellular traps 
(NETs), leukocyte activation, and platelet activation [9].
TF expression in tumor cells has been shown to increase with histologic grade in many 
cancer types, including pancreatic cancer [10–12]. TF is the primary initiator of the extrinsic 
pathway of the coagulation cascade that culminates in thrombin generation and fibrin 
formation [13–15]. Thrombin is a particularly potent platelet agonist, mediating the 
activation of human platelets via Par1 and Par4 and mouse platelets via Par3 and Par4 [16].
MVs (also called microparticles or extracellular vesicles) are small membrane vesicles that 
are constitutively released by tumor cells [17, 18]. We will refer to these as tumor-derived 
MVs (TMVs). Importantly, the presence of TF makes MVs highly procoagulant [19, 20]. 
Several studies have shown that MVs released from human pancreatic tumor cell lines and 
human pancreatic tumors grown in mice contain TF [17, 21, 22]. Other studies have reported 
increased plasma TF+ MVs and MV TF activity in patients with different cancer types [23–
27]. Further, increased levels of TF+ MVs and MV TF activity are associated with VTE in 
pancreatic cancer patients, which suggests a role for TF+ MVs in cancer-associated 
thrombosis [23, 24, 28, 29].
Previous studies by our lab and others have shown that TF+ TMVs from human breast and 
pancreatic adenocarcinoma cell lines trigger the activation of coagulation and platelets in 
mice [17, 30]. Thomas and colleagues showed that mice with TF+ Panc02 tumors, a mouse 
pancreatic adenocarcinoma cell line, had larger thrombi than control mice in a ferric 
chloride injury-induced mesenteric vessel model, and that TF+ TMVs from Panc02 cells 
enhanced thrombosis in wild-type (WT) mice [22]. We showed that mice with tumors 
derived from the human pancreatic adenocarcinoma cell line HPAF-II had shorter occlusion 
times than controls in ferric chloride injury-induced saphenous vein thrombosis, and that 
injection of exogenous TF+ TMVs enhanced thrombosis in the inferior vena cava (IVC) 
stenosis model in WT mice [30]. More recently, it was shown that mice containing TF+ 
Panc02 tumors had larger thrombi than control mice in the cremaster laser injury model and 
that this enhanced thrombosis was reduced by treatment with the anti-platelet drug 
clopidogrel [31]. In addition, mice bearing TF+ Panc02 tumors had increased thrombosis in 
the IVC stenosis model [32]. Tumor cells have been shown to induce platelet aggregation 
through a variety of mechanisms, including via thrombin generation [33]. Furthermore, MVs 
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derived from SOJ6 pancreatic adenocarcinoima cells triggered aggregation of washed 
platelets in the presence of plasma [22].
In this study, we determined the effect of TF+ TMVs on platelets in vitro and in vivo. Our 
studies suggest that TF+ TMVs enhance thrombosis in mice, in part, in a platelet-dependent 
manner.
Materials and methods
Reagents and antibodies
We used the following reagents: clopidogrel (Bristol-Myers Squib, New York, NY, USA), 
prostaglandin E1 (PGE1) (Cayman Chem, Ann Arbon, MI, USA), anti-human TF antibody 
(HTF-1), anti-αvβ3 antibody (LM609), the substrate benzyloxycarbonyl-Gly-Gly-Arg-7-
amido-4methylcoumarin• HCl (Z-GGR-AMC) (Bachem, Torrance, CA, USA), annexin V- 
Pac Blue (Life Technologies, Grand Island, NY, USA), Megamix beads (Biocytex, 
Marseille, France), anti-CD41a-R-Phycoerythrin (PE) (clone HIP8), anti-CD62P-
allophycocyanin (APC) (clone AK-4), Pac-1-fluorescein (FITC), PE-IgG isotype control and 
anti-CD142-PE (clone HTF-1), anti-PSGL-1 (clone KPL-1), anti-CD24 (clone ML5), 
annexin V (BD Biosciences, San Jose, CA, USA), citrated mouse plasma, mouse IgG, 
apyrase, 2 Methylthioadenosine 5′-monophosphate (MesAMP), and acid citrate dextrose 
(ACD) (Sigma, Saint Louis, MO, USA), hirudin (Accurate Chem and Scientific, Westbury, 
NY, USA), active site-inhibited recombinant FVIIa (FVIIai) (American Diagnostica, 
Stamford, CT, USA), human α-thrombin (Thermo Scientific, Waltham, MA, USA), 
recombinant relipidated human TF (InnovinTM) (Dade Behring, Liederbach, Germany), 
5(6)-Carboxyfluorescein diacetate succinimidyl ester (CFSE) (eBioscience, San Diego, CA, 
USA), anti-GPIX (clone Xia.B4) (Emfret Analytics, Eibelstdt, Germany), Enzygnost TAT 
micro ELISA kit (OWMG15) (Siemans Healthcare Diagnostics, Malvern, PA, USA), and 
the mouse CXCL4/PF4 DuoSet ELISA (R&D Systems, Minneapolis, MN, USA).
Cell Lines
The human pancreatic adenocarcinoma cell lines BxPc-3 and L3.6pl were obtained from the 
American Type Culture Collection (ATCC) (Manassas, VA, USA) and cultured in RPMI 
(Gibco, Grand Island, NY, USA) plus 10% fetal bovine serum (Omega Scientific, Tarzana, 
CA, USA) and 1% penicillin streptomycin (Gibco). MVs were isolated from 72 hour serum-
free cell culture supernatant. Apoptotic bodies and cell debris were pre-cleared from culture 
supernatant by centrifugation at 2612 x g for 5 minutes. MVs were then pelleted at 20,000 x 
g for 20 minutes at 4°C, re-suspended in PBS, and stored at 80°C until use. MV 
concentration was determined by protein content using a BCA protein assay (Thermo 
Scientific, Rockford, IL, USA).
Human Subjects
Healthy non-pregnant adults were recruited into this study under IRB approval from the 
office of Human Research Ethics at University of North Carolina and informed consent was 
obtained. Blood was collected from the antecubital vein into ACD and 1 μg/mL PGE1. The 
first 3 mL of blood was discarded. Platelet-rich plasma (PRP) was isolated by centrifugation 
Geddings et al. Page 3
J Thromb Haemost. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
at 230 x g for 15 minutes at room temperature. PRP was then spun at 920 x g for 10 minutes 
with one Tyrode’s buffer wash step to isolate platelets. Platelets were re-suspended in 
Tyrode’s buffer without calcium.
Mice
All experiments used 8–22 week old C57Bl6/J male mice. Studies were approved by the 
Institutional Animal Care and Use Committee at the University of North Carolina and 
comply with NIH guidelines. C57Bl6/J and nude mice were obtained from Jackson 
laboratories (Bar Harbor, Maine, USA). Par4 knockout mice (−/−) and WT (+/+) littermate 
controls were obtained from Dr. Shaun Coughlin (University of California at San Francisco, 
CA, USA). WT mice were treated with clopidogrel (75 mg/kg) by oral gavage 24 hours and 
1 hour before experimentation. Efficacy of this treatment was confirmed by the inability of 
platelets in clopidogrel treated mice to respond to 2.5 μm ADP (MFI of the anti-active 
αIIb/β3 antibody JonA-PE binding: saline without ADP 20.7 ±2.8; saline with ADP 38.9 ± 
3.2; clopidogrel without ADP 20.7 ± 1.4; clopidogrel with ADP 13.4 ± 0.94). Orthotopic 
tumor injection of nude mice was performed as described [30]. Tumors were allowed to 
grow to 2 cm3 in size over 8–16 weeks.
Microscopy
Isolated MVs were visualized using a Tecnai 12 transmission electron microscopy (TEM) 
(FEI, Hillsboro, OR) at 80 kV, and images were captured on a Gatan Orius charge-coupled 
device (CCD) camera programmed with Digital Micrograph software (Gatan, Warrendale, 
PA).
TF activity
Cellular and MV TF activity assays were performed described [34, 35].
Flow Cytometry
Washed human platelets were re-suspended to a concentration of 5 × 108 plt/mL in Tyrode’s 
buffer containing 1 mM CaCl2. Platelets were incubated with 2 μL anti-CD41a-PE, anti-P-
selectin-APC, and Pac-1-FITC. TMVs were incubated with platelets for 15 minutes at 37°C. 
Platelet reactions were then diluted in Tyrode’s buffer containing 0.5% formalin. For MV 
ligand studies, 0.1 μg of MVs were stained with 2 μL antibody in 100 μL of staining buffer 
(140 mM NaCl, 10 mM Hepes, 5 mM CaCl2) for 30 minutes on ice. Samples were diluted 
before analysis. Megamix beads were used to set an upper size limit of 1 μm for MVs. 
Platelet and MV samples were analyzed using a Stratedigm Ex1000 flow cytometer 
(Stratedigm, San Diego, CA). Data were analyzed using Flowjo version X.0.7 software.
Thrombin Generation Assay
We measured thrombin generation using a calibrated automated thrombogram (CAT) using 
PRP as described [36].
Geddings et al. Page 4
J Thromb Haemost. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Platelet Aggregometry
Human or mouse washed platelets were re-suspended to 6 × 108 plt/mL in Tyrode’s buffer 
containing 1 mM CaCl2, 0.35% BSA, and 1:100 mouse or human plasma. Aggregation was 
triggered by the addition of BxPc-3 or L3.6pl MVs. Reactions were performed with stirring 
(1200 RPM) at 37°C in a Chrono-log 4-channel optical aggregation system (Chrono-log, 
Havertown, PA).
Mouse Thrombosis and Pulmonary Embolism Models
Femoral and IVC thrombosis models were performed as described [37, 38]. For the 
pulmonary embolism model, platelets were visualized with an infrared-labeled anti-GPIX 
antibody and platelet deposition in lungs imaged on an Odyssey Infrared imaging system 
(LI-COR, Lincoln, NE, USA) as described [39].
TF Expression in Tumors
Paraffin-embedded tumor tissue was incubated with either anti-human TF goat polyclonal 
antibody (R&D Systems, Minneapolis, MN) or a control IgG (Santa Cruz, Dallas, TX). A 
biotinylated anti-goat rabbit polyclonal antibody was used for detection and slides were 
incubated with DAB (DAKO, Carpinteria, CA) and counterstained with hematoxylin.
Statistical Analysis
Data are presented as mean ± SEM. TF activity and TF antigen expression data were 
analyzed by unpaired student’s t-test. Flow cytometry, thrombin generation, and thrombosis 
model data were analyzed by one- or two-way ANOVA as indicated with Bonferroni 
posttests comparing indicated pairs of data. Survival data were analyzed using Log-rank 
(Mantel-Cox) Test. Statistical significance is defined on each figure. Statistical analysis was 
performed on GraphPad Prism software version 5.01 (Graph Pad Software, Inc. La Jolla, 
CA, USA).
Results
TF expression by two human pancreatic cell lines
We focused our studies on two TF-expressing human pancreatic adenocarcinoma cell lines 
that expressed high (BxPc-3) and low (L3.6pl) levels of TF (Figure 1A). BxPc-3 and L3.6pl 
cells are moderately and poorly differentiated pancreatic adenocarcinoma cell lines, 
respectively [40]. The BxPc-3 cell line was established from a primary human tumor 
whereas the L3.6pl cell line was established from a more metastatic isolate of the human 
pancreatic adenocarcinoma cell line COLO 357 [41, 42]. MVs isolated from BxPc-3 and 
L3.6pl cells were imaged using electron microscopy to determine their size and purity 
(>95% vesicles <0.9 μm in size) (Figure 1B). MVs isolated from the cell culture supernatant 
of BxPc-3 cells had 58-fold more TF activity than MVs from L3.6pl cells (Figure 1C) and 
had more TF antigen (Figure 1D). Immunohistochemical analysis of TF expression in 
tumors demonstrated higher levels in BxPc-3 tumors than L3.6pl tumors (Figure 1E).
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Interaction of TF+ TMVs with platelets
A previous study reported that the human pancreatic adenocarcinoma cell line SOJ-6 
expressed PSGL-1 which was involved in the binding of TMVs to activated platelets [22]. 
We analyzed expression of the P-selectin ligands PSGL-1 and CD24 on MVs from BxPc-3 
and L3.6pl cells. BxPc-3 MVs expressed CD24 but not PSGL-1 whereas neither ligand was 
present on L3.6pl MVs (Figure 2A). We evaluated the ability of BxPc-3 and L3.6pl TF+ 
MVs to interact with washed human platelets in vitro. Both MV types associated with 
platelets in a dose dependent manner (Figure 2B). Further, incubation of TF+ MVs with 
washed human platelets resulted in delivery of MV TF to platelets (Figure 2C). Platelets 
incubated with BxPc-3 MVs had 59-fold higher TF activity than platelets incubated with 
L3.6pl MVs. Blocking phosphatidylserine (PS) with annexin V on platelets or TMVs did not 
reduce the interaction of TMVs with platelets (Figure 2D and data not shown). Similarly, 
blocking αvβ3 with the antibody LM609 did not reduce the TMV-platelet interaction 
(Figure 2D). Finally, we analyzed the ability of TMVs to trigger thrombin generation in 
PRP. We have previously shown that adding TF shortens the lag time in the CAT assay in a 
dose-dependent manner [36]. Both BxPc-3 and L3.6pl MVs shortened the lag time (Figure 
2E). We observed that the lag times were on average 3.9 +/- 0.9 times shorter with BxPc-3 
MVs compared with L3.6pl MVs using PRP from 3 donors. These data indicate that TMVs 
from two pancreatic cell lines interact with resting platelets resulting in the delivery of TF.
TF+ TMVs activate platelets
TF+ MVs from both BxPc-3 and L3.6pl cells activated platelets in the presence of plasma 
(Figure 3A). Inhibition of the TF/FVIIa complex with either HTF-1 or FVIIai blocked TF+ 
MV-induced platelet activation (Figure 3B and C). The percent inhibition of platelet 
activation by HTF-1 for BxPc-3 and L3.6pl MVs was 94.1% and 100.0%, and for FVIIai 
was 93.2% and 100.0%, respectively. As demonstrated above, TF+ MVs trigger the 
generation of thrombin in the presence of plasma, making thrombin the most likely 
candidate for the indirect mediator of TF+ TMV-induced platelet activation. To confirm this 
notion, BxPc-3 and L3.6pl MVs were incubated with platelets and diluted plasma in the 
presence of the thrombin inhibitor hirudin. Hirudin inhibited both BxPc-3 (percent inhibition 
93.6%) and L3.6pl (percent inhibition 99.7%) MV-induced platelet activation (Figure 3C). 
MV-induced platelet activation was also inhibited by ADP scavenger apyrase or P2Y12 
receptor inhibitor 2 MesAMP (Figure 3C). Representative dot plots are shown in 
Supplementary Figure 1.
TF+ TMVs induce platelet aggregation
BxPc-3 and L3.6pl MVs induced human platelet aggregation in a dose-dependent manner in 
the presence of human plasma (Figure 4A). Since BxPc-3 MVs have a high level of TF 
activity they triggered platelet aggregation more quickly than L3.6pl MVs (Figure 4A). 
BxPc-3 and L3.6pl MV-induced platelet aggregation was dependent on the presence of both 
MV TF (Figure 4B) and thrombin (Figure 4C). A P-selectin blocking antibody had no effect 
on MV-induced platelet aggregation (data not shown). In order to confirm that these TMVs 
could be used in mice, aggregometry experiments were also performed using mouse 
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platelets. BxPc-3 and L3.6pl MVs triggered thrombin-dependent mouse platelet aggregation 
in the presence of mouse plasma (Figure 4D).
Effect of BxPc-3 tumors and exogenous TF+ TMVs on the activation of coagulation and 
thrombosis in mice
We determined the effect of orthotopic tumors on levels of MV TF activity, coagulation 
activation, platelet activation and venous thrombosis in mice. We used BxPc-3 MVs because 
they express higher levels of TF. We detected a low level of MV TF activity in the plasma 
of 2 out of 4 nude mice with BxPc-3 tumors (Figure 5A). Some of this variation appears to 
be due to tumor size. Tumor-bearing mice had increased plasma TATc but there was no 
increase in plasma PF4 (Figure 5B and C). In addition, tumor-bearing mice developed 
significantly larger thrombi in the IVC stenosis model in comparison to PBS controls with 
no significant increase in thrombus incidence (Figure 5D and E).
There may be several pathways that contribute to enhanced thrombosis in tumor-bearing 
mice. Therefore, we chose to specifically evaluate the role of TF+ TMVs by injecting 
exogenous MVs into mice. Injection of BxPc-3 MVs into WT mice without IVC stenosis 
significantly increased the level of MV TF activity in the plasma (Figure 6A). The level of 
MV TF activity observed with exogenous BxPc-3 MVs was ~10-fold higher than the levels 
observed in tumor bearing mice. Injection of BxPc-3 MVs into mice also increased plasma 
TATc and PF4 (Figure 6B and C) and lead to death of mice (data not shown). In contrast, 
injection of the same amount of L3.6pl TMVs into WT mice without IVC stenosis did not 
increase MV TF activity or induce death (data not shown). Injection of BxPc-3 TMVs into 
mice that also underwent IVC stenosis had an increase inthrombus size, thrombus incidence, 
and reduced survival (Figure 6D–F). In addition, TF+ TMVs-enhanced platelet and fibrin 
accumulation in a mouse femoral vein thrombosis model (Supplementary Figure 2).
Role of TF and platelet activation in TMV-enhanced thrombosis in mice
Incubation of the BxPc-3 MVs with an anti-human TF antibody (HTF-1) prior to injection 
abolished the increase in thrombus size, decreased thrombus incidence and increased 
survival (Figure 6D–F). Similarly, both platelet and fibrin accumulation was significantly 
reduced in the femoral vein thrombosis model by pre-treatment of the TMVs with HTF-1 
(Supplementary Figure 2). Interestingly, addition of the HTF-1-treated TMVs reduced fibrin 
accumulation levels to below that of the vehicle-treated mice.
Next, we determined the role of platelets in TF+ TMV-enhanced thrombosis. TF+ TMV-
enhanced thrombosis was significantly reduced in Par4−/− mice compared to WT littermate 
controls (Figure 7A). A deficiency of Par4 did not affect thrombus incidence or survival 
(Figure 7B and C). Similarly, treatment of WT mice with the P2Y12 receptor inhibitor 
clopidogrel reduced the size in TMV treated mice at all time points (Figure 7D). Clopidogrel 
did not affect thrombus incidence at most time points and did affect survival (Figure 7E and 
F).
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Intravenous Injection of TF+ TMVs increases lung platelet deposition in mice
We suspected that death of the mice receiving TF+ TMVs was due to formation of platelet-
rich clots in the lungs. To examine this we injected BxPc-3 TMVs into WT mice without 
IVC stenosis and measured platelet deposition in the lungs. We found that platelet 
deposition in the lungs was increased with injection of BxPc-3 TMVs into mice, which 
suggests that TMV-induced platelet activation is occurring in vivo (Figure 8A and B). We 
have previously shown that accumulation of labeled platelets in the lung is associated with 
platelet-rich thrombi in the lung vasculature [39].
Discussion
Cancer-associated thrombosis is a major clinical problem and is likely mediated by multiple 
mechanisms in different types of cancer [9]. In this study, we analyzed the role of TF+ 
TMV-enhanced platelet activation as a mechanism that contributes to cancer-associated 
thrombosis. We found that TF+ TMVs from two human pancreatic adenocarcinoma cell 
lines interact with resting platelets and activate them via thrombin generation.
What mediates the interaction between TMVs and platelets? Previous studies have shown 
that platelet binding of MVs derived from LPS stimulated human monocytes or the 
monocytic cell line THP-1 is mediated by PSGL-1 on the MV interacting with P-selectin on 
the activated platelet [43, 44]. Del Conde and colleagues found that 17% of the activated 
platelets acquired MV TF in a 30 minute incubation [43]. In contrast, little binding was 
observed when the monocyte MVs were incubated with unstimulated platelets. Ghosh and 
colleagues found that inhibition of CD36 reduced binding of endothelial, monocyte, and 
platelet MVs to resting platelets [45]. Moreover, annexin V or an antibody to PS also 
reduced MV binding to platelets, suggesting a role for MV PS in binding [45]. However, we 
did not observe any effect of annexin V on the binding of TMVs to resting platelets when 
incubated with the platelets or the MVs. Thomas and colleagues reported PSGL-1 
expression by the human pancreatic cell line SOJ-6 and the mouse pancreatic cell line 
Panc02 and suggested that an interaction between MV PSGL-1 and platelet P-selectin 
mediated the docking of TMVs to the growing thrombus [22]. In contrast, a recent study 
found that neither P-selectin nor GP1b were required for TMV recruitment to the site of 
thrombosis in the IVC stenosis model [32]. We did not detect PSGL-1 expression on MVs 
derived from BxPc-3 and L3.6pl. Furthermore, inhibition of P-selectin did not reduce TMV-
induced platelet aggregation (data not shown). This suggests that the observed interaction 
between BxPc-3 and L3.6pl MVs and resting platelets is not mediated by an interaction 
between PSGL-1 and P-selectin. More recently, it was reported that “Panc02 cancer cell-
derived microparticles firmly adhere at the site of injury to fibrinogen present on activated 
platelets forming a thrombus” [31]. In addition, an inhibitor of the integrins αvβ1/β3 reduced 
the accumulation of Panc02 to the site of vessel injury in mice [31]. However, we did not 
observe any effect of either the integrin αvβ3 inhibitory antibody LM609 or annexin V on 
the interaction of BxPc-3 MVs with resting platelets. These differences may be due to the 
fact that MVs derived from different tumor lines have different cell surface receptors. 
Indeed, we have found marked differences in cell surface receptors on MVs derived from 4 
human pancreatic cancer cells lines (BxPc-3, L3.6pl, HPAC and PANC-1) (Figure 2A and 
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data not shown). Additional studies are needed to determine the mechanisms by which 
different TMVs interact with platelets.
We showed that TF+ TMVs activate washed platelets and induce platelet aggregation in the 
presence of plasma. This activation was dependent on both TF and thrombin. An earlier 
study showing that MVs from the human pancreatic cancer cell line SOJ-6 induced 
aggregation of washed platelets in the presence of plasma but not in the absence of plasma 
[22]. Furthermore, aggregation was abolished with FVII-depleted plasma but not with 
fibrinogen-depleted plasma. Taken together, these results indicate that TF+ TMVs from 
several different human pancreatic cell lines induce aggregation of platelets in vitro.
We found that injection of BxPc-3 MVs into mice increased plasma TATc, a marker of 
activation of coagulation, and PF4, a marker of platelet activation. Furthermore, BxPc-3 MV 
injection increased platelet accumulation in the lungs and resulted in death from suspected 
pulmonary embolism. A previous study found that injection of MVs from either TF+ human 
breast cancer cell line MDA-MB-231 or L3.6pl cells led to acute thrombocytopenia and 
signs of shock [17]. We found that TMV-enhanced thrombosis was abolished by inhibiting 
TF on the MV. In addition, TMV-enhanced thrombosis was reduced in mice lacking Par4 
and in wild-type mice treated with clopidogrel. This suggests that platelet activation plays a 
role in TMV-enhanced thrombosis (Figure 8C). A limitation of these experiments is that 
deficiency of Par4 or administration of clopidogrel to WT mice will also reduce basal 
thrombosis. Low molecular-weight heparin (LMWH) or clopidogrel reversed the 
prothrombotic phenotype observed in mice bearing Panc02 tumors in a laser-injury model 
[31]. TF+ MVs have been detected in patients with various cancers, including breast and 
pancreatic cancer [23, 46]. Therefore, TF+ MVs may contribute to thrombosis in patients 
with different types of cancers.
LMWH is the recommended treatment for VTE in patients with cancer [47, 48]. However, 
VTE recurs in 6–9% of patients despite therapy [49–53]. Currently, the only evidence-based 
option for treating recurrent VTE in cancer patients despite secondary thromboprophylaxis 
is LMWH dose escalation [54]. Interestingly, there is clinical evidence for the involvement 
of platelets in cancer-associated thrombosis [55]. For instance, thrombocytosis is a risk 
factor for VTE in cancer patients, many of whom have increased plasma markers of platelet 
activation [56–61]. Although aspirin had a marginal effect (p=0.053) in ovarian cancer 
patients and had no effect on VTE risk in breast cancer patients in two retrospective studies, 
it reduced VTE as effectively as LMWH in multiple myeloma patients [62–64]. These data 
suggest that anti-platelet drugs may be beneficial in the prevention of cancer-associated 
thrombosis.
Non-cancer patients who develop a VTE are treated acutely with LMWH and then bridged 
to a vitamin K antagonist or treated with the new oral anticoagulants. However, clinical 
trials have found that long-term LMWH is more effective than vitamin K antagonists at 
reducing VTE recurrence in cancer patients [48, 51, 52]. These studies suggest that the 
pathophysiology of VTE in cancer patients is different from non-cancer patients. Our mouse 
study and the recent study by Mezouar and colleagues [31] suggest that anti-platelet drugs, 
Geddings et al. Page 9
J Thromb Haemost. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
such as clopidogrel, may reduce cancer-associated VTE in cancer patients with high levels 
of circulating TF+ TMVs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Essentials
• Cancer patients have a high rate of venous thrombosis but the underlying 
mechanisms are unkown.
• The study investigates the role of tumor-derived, tissue factor-positive 
microvesicles in platelet activation in vitro and in vivo.
• Tumor-derived, tissue factor microvesicles activated platelets in vitro and 
enhanced venous thrombosis in mice.
• Platelets may contribute to venous thrombosis in some cancer patients and this 
could be prevented with anti-platelet drugs.
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Figure 1. TF expression on tumor cells, tumor cell-derived microvesicles and tumors
(A) Cellular tissue factor (TF) activity was measured using a one stage clotting assay. 
*P<0.001, n=6. (B) BxPc-3 and L3.6pl MVs were imaged by transmission electron 
microscopy. (C) Microvesicle (MV) TF activity was measured using a two-stage clotting 
assay. *P<0.005, n=4. TF activity was normalized to total protein. (D) TF antigen 
expression on MVs was analyzed by MV flow cytometry. Representative histograms are 
shown and the mean fluorescence intensity (MFI) of an anti-TF antibody is reported. Data 
were analyzed by unpaired student’s t-test. (E) Human TF expression in BxPc-3 and L3.6pl 
orthotopic tumors from mice.
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Figure 2. Binding of TF positive tumor microvesicles to platelets
(A) Expression of the P-selectin ligands PSGL-1 and CD24 was evaluated on MVs isolated 
from BxPc-3 and L3.6pl cells by flow cytometery. Representative histograms are shown. (B) 
BxPc-3 and L3.6pl TMVs were stained with 4 μM CFSE fluorescent dye followed by 2 
wash steps at 20,000 x g for 20 minutes. The indicated concentrations of stained TMVs or 
washed supernatant were incubated with human platelets in the presence of 1:100 diluted 
human plasma for 15 minutes at 37°C in the presence of anti-human CD41a-PE. TMV-
platelet binding was quantified by measuring the percentage of CFSE-positive platelet 
events by flow cytometry. A representative experiment of 3 independent experiments is 
shown. (C) Washed human platelets were incubated with 10 μg of BxPc-3 MVs (20 pg TF), 
10 μg of L3.6pl MVs (0.4 pg TF), 0.5 pg of Innovin TF, or vehicle control for 15 minutes at 
37°C. Platelets were then washed and cellular TF activity was determined to quantify the 
delivery of TMV TF to platelets. *P<0.0001, n=3. TF activity was normalized to total 
protein. (D) Incubation of platelets with either annexin V (2.5 μg/mL final concentration) or 
the anti-αvβ3 antibody LM609 (1:100 dilution) at room temperature for 15 minutes did not 
reduce the amount of TF delivered from either 5 or 2.5 μg/mL of BxPc-3 MVs. Data were 
analyzed by one-way ANOVA with Bonferroni posttests comparing indicated pairs of data. 
(E) BxPc-3 and L3.6pl MVs led to a dose-dependent shortening of lag time in a calibrated 
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automated thrombogram with platelet-rich plasma. The PRP trigger reagent (1 pM TF) was 
added to the positive control and buffer was added to the negative control. Data are shown 
from one donor representative of 3 different donors.
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Figure 3. Tumor microvesicles induce platelet activation in a tissue factor and thrombin-
dependent manner
(A) BxPc-3 (black bars) and L3.6pl (grey bars) microvesicles (MVs) (50 μg protein/mL) 
were incubated with washed human platelets in the presence and absence of diluted human 
plasma (1:100). Platelet activation was monitored by flow cytometry for Pac-1 binding to 
activated αIIb/β3 and P-selectin expression. Data are presented as the mean fluorescence 
intensity (MFI) of total CD41a-positive events (+/- SEM). Data are representative of 3 
independent experiments. *P<0.01, n=3. Data were analyzed by one-way ANOVA with 
Bonferroni posttests comparing indicated pairs of data on Graphpad Prism software v5.01. 
(B) BxPc-3 and L3.6pl MVs (50 μg protein/mL) were pre-incubated with HTF-1 (50 μg/ml) 
or IgG control (50 μg/ml) for 30 minutes at 4°C. TMVs were then incubated with human 
platelets in the presence of diluted human plasma (1:100). Data are presented as the MFI of 
total CD41a-positive events (+/- SEM). Data are representative of 3 independent 
experiments. *P<0.0001, n=3. (C) Platelets were pre-incubated with inhibitors as indicated 
for 5 minutes at room temperature. BxPc-3 and L3.6pl MVs (50 μg/mL) were then incubated 
with human platelets in the presence of diluted plasma for 15 minutes at 37°C. Recombinant 
TF (InnovinTM) (0.5 pg) and alpha-thrombin (5 nM) were used as controls. After the 
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activation reaction was complete, the reactions were diluted in Tyrode’s buffer + 1 mM 
CaCl2 + 0.5% formalin and P-selectin expression evaluated by flow cytometry. Data are 
presented as the MFI of total CD41a-positive events (± SEM). Data are representative of 3 
independent experiments. *P<0.0001, n=3. Data were analyzed by one-way ANOVA with 
Bonferroni posttests comparing all data to the no MV control.
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Figure 4. Tumor microvesicles induce platelet aggregation in a tissue factor and thrombin-
dependent manner
Washed human platelets were re-suspended in Tyrode’s buffer containing human plasma at 
a dilution of 1:100. (A) Platelets were stimulated with the indicated concentrations of 
BxPc-3 or L3.6pl microvesicles (MVs). (B) MVs were pre-incubated with the inhibitory 
anti-TF antibody HTF-1 (50 μg/ml) or IgG control (50 μg/ml) for 30 minutes prior to being 
added to platelets. Platelets were then stimulated with either BxPc-3 or L3.6pl MVs (50 μg 
protein/mL). (C) The direct thrombin inhibitor hirudin (1 U/ml) or vehicle control were pre-
incubated with platelets for 5 minutes at room temperature prior to the addition of MVs. 
Platelet aggregation was monitored by light transmittance and is reported as percent 
absorbance. Tracings are representative of 3 independent experiments. (D) Washed mouse 
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platelets were re-suspended in Tyrode’s buffer containing mouse plasma at a dilution of 
1:100. Hirudin, or vehicle control were pre-incubated with platelets for 5 minutes at room 
temperature. Platelets were then stimulated with BxPc-3 or L3.6pl MVs (50 μg protein/mL). 
Platelet aggregation was monitored by light transmittance and is reported as percent 
absorbance.
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Figure 5. Effect of BxPc-3 tumors on thrombosis in mice
(A–E) BxPc-3 cells or PBS were injected into the pancreas of nude mice. Tumors were 
allowed to develop for 8–16 weeks until tumors reached a maximum of 2 cm3 in size. Blood 
was drawn from the inferior vena cava (IVC) and plasma collected and stored at −80°C. 
Levels of (A) microvesicles (MV) tissue factor activity (TF), (B) thrombin-antithrombin 
complexes (TATc) and (C) platelet factor 4 (PF4) were measured in mouse plasma from 
tumor-bearing mice and controls. (*P<0.05, PBS n=10, BxPc-3 n=5). Data were analyzed 
by unpaired student’s t-test. Tumor weights (g) with detectable MV TF activity are indicated 
in panel A. Mice with tumor weights of 1.9 g and 0.3 g did not have detectable MV TF 
activity. (D) Thrombosis was induced in BxPc-3 tumor-bearing nude mice or PBS controls 
by stenosis of the IVC. Thrombus formation was quantified in mice using high-frequency 
ultrasonography. Data is presented as mean ± SEM. (p<0.001. PBS n=6, BxPc-3 n=5). Data 
were analyzed by two-way ANOVA with Bonferroni posttests comparing all data to the PBS 
control at each time point. (E) Percent incidence of thrombosis is shown from the 
thrombosis experiments in panel D. There was no difference in thrombus incidence found by 
log-rank sums test between tumor bearing and non-tumor bearing mice.
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Figure 6. Effect of BxPc-3 Tumor Microvesicles on Thrombosis in Mice
(A–C) BxPc-3 tumor microvesicles (TMVs) (9 μg total) or the same volume of PBS control 
were injected into mice that did not undergo IVC stenosis at 5, 30, and 60 minutes. 
Immediately after the final injection, blood was drawn from the IVC and plasma collected 
and stored at −80°C. Levels of (A) MV TF activity, (B) TATc and (C) PF4 were measured 
in mouse plasma. *P<0.05, **P<0.0001, PBS n=5, BxPc-3 n=6. Data were analyzed by 
unpaired student’s t-test. (D-F) Thrombosis in mice was induced by IVC stenosis. Following 
stenosis, mice were injected intravenously with PBS, BxPc-3 MVs pre-incubated with IgG, 
or BxPc-3 MVs pre-incubated with the anti-TF antibody HTF-1 (1 mg/mL). (D) Thrombus 
formation was quantified in mice using high-frequency ultrasonography. Data is presented 
as mean ± SEM. *P<0.01. PBS n=7, BxPc-3 n=8, BxPc-3 + HTF-1 n=7. Data were analyzed 
by two-way ANOVA with Bonferroni posttests comparing all data to the no MV control at 
each time point. (E) Percent incidence of thrombosis is shown from the thrombosis 
experiment in panel D. Statistical significance was determined by log-rank sums test. (F) 
Mouse survival following MV injection in panel D is reported with death defined as 
permanent cessation of breathing within 5 minutes of MV injection. *P<0.05. PBS and 
BxPc-3 + HTF-1 n=7, BxPc-3 + IgG n=14. Survival data were analyzed by log-rank 
(Mantel-Cox) test.
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Figure 7. TF+ tumor microvesicles enhance thrombosis in mice in a platelet-dependent manner
(A–C) Par4 KO mice (−/−) or WT (+/+) littermate controls underwent the inferior vena cava 
(IVC) stenosis model followed by injection of BxPc-3 MVs at 5 minutes, 30 minutes, and 1 
hour (9 μg total). (A) Thrombus development was quantified by high-frequency 
ultrasonography. Data were analyzed by one-way ANOVA and are statistically significant 
for Par4+/+ + MVs versus Par4−/− + MVs. P<0.001, Par4+/+ n=6, Par4−/− n=5. (B) Percent 
incidence of thrombosis is shown from the thrombosis experiment in panel A. No difference 
was found by log-rank sums test. (C) Mouse survival following MV injection in panel A is 
reported with death defined as permanent cessation of breathing within 5 minutes of MV 
injection. Survival data were analyzed by log-rank (Mantel-Cox) test. (D-F) Clopidogrel or 
vehicle treated wild-type mice were subjected to IVC stenosis followed by BxPc-3 MV 
injection as above and (D) thrombus formation was quantified by high-frequency 
ultrasonography. Data were analyzed by one-way ANOVA and are statistically significant 
for MVs + clopidogrel versus MVs + vehicle control. P<0.001, BxPc-3 MVs + vehicle n=5, 
BxPc-3 MVs + clopidogrel n=6. (E) Percent incidence of thrombosis is shown from the 
thrombosis experiments in panel D. No difference was found by log-rank sums test. (F) 
Mouse survival following MV injection in panel D is reported with death defined as 
permanent cessation of breathing within 5 minutes of MV injection. Survival data were 
analyzed by log-rank (Mantel-Cox) test.
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Figure 8. TF+ tumor microvesicles induce accumulation of platelets in the mouse lung
(A) C57Bl6J mice were treated with an infrared-labeled anti-mouse GPIX antibody (0.125 
μg/g). Mice were then injected intravenously with BxPc-3 microvesicles (MVs) at 5, 30, and 
60 minutes (9 μg total) or the same volume of PBS control. Mice were sacrificed 5 minutes 
after the last injection, the lungs were removed and platelet deposition imaged on an 
Odyssey Infrared imaging system. Quantification of lung fluorescence was performed on 
ImageJ software. *P<0.0001, n=4 by unpaired student’s t-test. (B) Representative lung 
images are shown from mice injected with MVs or PBS. Some mice would start to gasp and 
then die within minutes of TMV injection. (C) Proposed pathways by which TF+ TMVs 
enhance venous thromboembolism (VTE).
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